Medications for Cystic Fibrosis
8 results
Acetylcysteine (acetylcysteine)
(Acetylcysteine)Somerset Therapeutics, LLC
Usage: Acetylcysteine solution, USP is indicated as adjuvant therapy for abnormal mucous secretions in chronic and acute bronchopulmonary diseases, pulmonary complications of cystic fibrosis, tracheostomy care, surgical pulmonary complications, anesthetic use, post-traumatic chest conditions, atelectasis due to mucous obstruction, and diagnostic bronchial studies.
Alyftrek (vanzacaftor, tezacaftor, and deutivacaftor)
(vanzacaftor, tezacaftor, and deutivacaftor)Vertex Pharmaceuticals Incorporated
Usage: ALYFTREK is indicated for treating cystic fibrosis in patients aged 6 and older with at least one F508del mutation or another responsive CFTR mutation. An FDA-cleared CF mutation test is recommended if the patient's genotype is unknown.
Kalydeco (ivacaftor)
(ivacaftor)Vertex Pharmaceuticals Incorporated
Usage: KALYDECO is indicated for treating cystic fibrosis in patients aged 1 month and older with at least one responsive CFTR gene mutation, supported by clinical or in vitro evidence. An FDA-cleared CF mutation test is recommended for patients with unknown genotypes.
Orkambi (lumacaftor and ivacaftor)
(lumacaftor and ivacaftor)Vertex Pharmaceuticals Incorporated
Usage: ORKAMBI is indicated for treating cystic fibrosis in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. Its efficacy and safety in patients without this specific mutation have not been established.
South moon toothache (glycerin)
(GLYCERIN)Shantou South Moon Biotechnology Co., Ltd.
Usage: It appears there is no specific information provided in your message regarding the drug in question. Please provide the details or text from the drug label so I can assist you in summarizing its indications and usages.
Symdeko (tezacaftor and ivacaftor)
(Tezacaftor and Ivacaftor)Vertex Pharmaceuticals Incorporated
Usage: SYMDEKO is indicated for treating cystic fibrosis in patients aged 6 and older who are homozygous for the F508del mutation or have a responsive CFTR gene mutation. Genetic testing is recommended to identify the appropriate mutations before treatment.
Tobramycin inhalation (tobramycin inhalation)
(tobramycin inhalation)Prasco, LLC
Usage: Tobramycin Inhalation Solution is indicated for managing cystic fibrosis in patients with Pseudomonas aeruginosa. Its safety and efficacy are not established in individuals under six years, those with FEV1 less than 40% or greater than 80%, or patients colonized with Burkholderia cepacia.
Trikafta (elexacaftor, tezacaftor, and ivacaftor)
(Elexacaftor, Tezacaftor, and Ivacaftor)Vertex Pharmaceuticals Incorporated
Usage: TRIKAFTA is indicated for treating cystic fibrosis in patients aged 2 years and older with at least one F508del mutation or another responsive CFTR gene mutation. If the genotype is unknown, an FDA-cleared CF mutation test is required to confirm the presence of an indicated mutation.